Search Results for "Contrave"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contrave. Results 1 to 3 of 3 total matches.

Comparison Table: Some Drugs for Weight Management (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
Naltrexone/bupropion – Contrave (Currax) 8/90 mg ER tabs 16/180 mg PO bid Titration: 1 tablet qAM in week ...
View the Comparison Table: Some Drugs for Weight Management
Med Lett Drugs Ther. 2025 Aug 4;67(1734):e127-30   doi:10.58347/tml.2025.1734b |  Show IntroductionHide Introduction

Dextromethorphan/Bupropion (Auvelity) for Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
(Contrave) is approved for weight management. PHARMACOLOGY — Dextromethorphan is an analog of the opioid ...
The FDA has approved an extended-release fixed-dose combination of dextromethorphan and bupropion (Auvelity – Axsome) for treatment of major depressive disorder (MDD) in adults.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):201-3 |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
Naltrexone/bupropion – Contrave (Currax) 8/90 mg ER tabs 16/180 mg PO bid13 2-4%/31-54% 625.20 Lipase ...
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8   doi:10.58347/tml.2025.1734a |  Show IntroductionHide Introduction